Lantern Pharma Inc. (LTRN) has a negative trailing P/E of 0.0, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -83,335.75%.
Criteria proven by this page:
Overall SharesGrow Score: 37/100 with 1/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2018 | -53.8 | 0.00 | -460.62 | 0.00 | - |
| 2019 | -38.6 | -0.98 | 99.29 | 0.00 | - |
| 2020 | -20.3 | -0.14 | 6.08 | 0.00 | - |
| 2021 | -7.0 | -0.37 | 1.22 | 0.00 | - |
| 2022 | -4.6 | -0.29 | 1.17 | 0.00 | - |
| 2023 | -2.9 | -0.24 | 1.13 | 0.00 | - |
| 2024 | -1.7 | 0.00 | 1.62 | 0.00 | - |
| 2025 | 0.0 | 0.00 | 0.01 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2018 | $-0.28 | $0.00 | $-1.73M | - |
| 2019 | $-0.39 | $0.00 | $-2.43M | - |
| 2020 | $-0.95 | $0.00 | $-5.91M | - |
| 2021 | $-1.13 | $0.00 | $-12.3M | - |
| 2022 | $-1.30 | $0.00 | $-14.09M | - |
| 2023 | $-1.47 | $0.00 | $-15.96M | - |
| 2024 | $-1,930.92 | $0.00 | $-20.78B | - |
| 2025 | $-1.57 | $0.00 | $-17.12B | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-1.91 | $-1.91 – $-1.91 | $1.95M | $1.95M – $1.95M | 1 |
| 2027 | $-2.02 | $-2.02 – $-2.02 | $14.6M | $14.6M – $14.6M | 1 |
| 2028 | $-2.11 | $-2.11 – $-2.11 | $33.8M | $33.8M – $33.8M | 1 |
| 2029 | $-2.20 | $-2.20 – $-2.20 | $0.00 | $0.00 – $0.00 | 1 |
| 2030 | $-2.38 | $-2.38 – $-2.38 | $0.00 | $0.00 – $0.00 | 1 |
